ARTICLE | Clinical News
Volociximab: Phase I started
November 17, 2008 8:00 AM UTC
Ophthotech began a multiple ascending-dose Phase I trial of intravitreous volociximab with or without 0.5 mg/eye of Lucentis ranibizumab from Genentech Inc. (NYSE:DNA, South San Francisco, Calif.) a...